Biosimilars And Biologics Market Size, Analysis, Future Bar, Top Players And Forecast To 2022 to 2032

BySanket Badgujar
Market Research

The Biosimilars And Biologics Market is expected to grow at a CAGR of 15.5% during the period 2022-2032. The market is valued at US$ 22,490.62 Mn in 2022 and is expected to reach a valuation of US$ 95,021.37 Mn by 2032.

FMI, in its business report, elaborates the historical and current scenario of the global Biosimilars and Biologics Market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Biosimilars and Biologics market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1250

COVID-19 Impact Analysis on Biosimilars and Biologics Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Biosimilars and Biologics market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Biosimilars and Biologics market.

Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Biosimilars and Biologics market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

Biosimilars and Biologics Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Biosimilars and Biologics market. Competitive information detailed in the Biosimilars and Biologics market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Biosimilars and Biologics market report.

Key players covered in the report include:

  • Pfizer Inc. (AC. Hospira)
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories
  • Biocon Limited
  • Mylan, Inc.
  • Amgen
  • Celltrion Inc.
  • Roche Diagnostics
  • Merck KGaA

Biosimilars and Biologics Market: Segmentation

Valuable information covered in the FMI’s Biosimilars and Biologics market report has been segregated into key segments and sub-segments.

By Product Class:

  • Epoetins
  • Filgrastims
  • Insulins
  • Growth Hormones
  • Alfa Interferons
  • Monoclonal Antibodies
  • Beta Interferons
  • Follitropins
  • Low-molecular-weight Heparins (LMWH).

By Application:

  • Rheumatoid arthritis
  • Anemia
  • Cancer
  • Diabetes
  • Others